RxDoctor Payments Data

Binoy Sheth, DPM

Podiatrist · Allen, TXNPI 1710346101

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $116,000 of the $121,083 with a category attached, or 95.8%. Nvision Biomedical Technologies, Inc. accounts for 95.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2020 at $69,194 and has fallen 98.3% since, to $1,150 in 2025. Among podiatrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$121,083in general payments, 2019–2025

Across 162 payments — averaging $747.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nvision Biomedical Technologies, Inc.$116K
  • Pylant Medical$1K
  • Stryker$1K
  • Amgen$643
  • Treace Medical Concepts, Inc.$597
  • Smith+Nephew$407
  • plus $1K from 15 others

What the payments were for

  • Royalty or licence$116,00096%
  • Food & beverage$3,8833%
  • Education$1,2001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$121,083 in reported general payments places this provider in the 95th percentile of 470 podiatrist providers in Texas.

See all podiatrist providers in Texas

Medicare billing

Part B allowed, 2024
$276,201
Medicare patients
431
Services billed
1,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox68$1,993
Gabapentin13$593
Methylprednisolone48$363
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen23$206
Cephalexin21$189
Mupirocin13$114
Naproxen28$81

Paid to pharmacies, not to this prescriber.

Other podiatrist in Allen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →